OPTN - OptiNose, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.46
-0.48 (-4.83%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.94
Open9.85
Bid9.18 x 900
Ask11.00 x 1300
Day's Range8.86 - 9.85
52 Week Range5.66 - 30.00
Volume106,129
Avg. Volume154,140
Market Cap390.361M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.68
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
Trade prices are not sourced from all markets
  • GlobeNewswire13 hours ago

    Optinose to Report First Quarter 2019 Financial Results and Corporate Updates on May 9, 2019

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the first quarter 2019, before market open on Thursday, May 9, 2019. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.

  • Benzingalast month

    OptiNose Analysts Projects Prescription Growth In 2019, Beyond

    OptiNose In c (NASDAQ: OPTN ) has introduced a new and simplified co-pay assistance program that's led to good script performance, according to Cantor Fitzgerald. The ear, nose and throat drugmaker expects ...

  • OptiNose, Inc. (OPTN) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    OptiNose, Inc. (OPTN) Q4 2018 Earnings Conference Call Transcript

    OPTN earnings call for the period ending December 31, 2018.

  • GlobeNewswire2 months ago

     Optinose Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Highlights

    Company reports fourth quarter and full year 2018 net XHANCE revenue of $3.0 million and $7.1 million XHANCE prescriptions increased 50 percent from Q3 to Q4 of 2018.

  • GlobeNewswire2 months ago

    Optinose to Report Fourth Quarter 2018 Financial Results and Corporate Updates on March 6, 2019

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the fourth quarter 2018, before market open on Wednesday, March 6, 2019. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.

  • GlobeNewswire2 months ago

    Optinose Announces Issuance of Four Additional U.S. Patents Covering XHANCE

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the United States Patent and Trademark Office (USPTO) recently issued four patents covering XHANCE® (fluticasone propionate) nasal spray. “We are pleased to further strengthen our intellectual property portfolio with the  addition of these patents.

  • GlobeNewswire2 months ago

    Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco

    YARDLEY, Pa., Feb. 15, 2019 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today.

  • Bucks County drug-device developer inks licensing deal worth a potential $45M
    American City Business Journals3 months ago

    Bucks County drug-device developer inks licensing deal worth a potential $45M

    Inexia obtained certain rights that will enable it to use Optinose’s exhalation delivery system when developing potential therapies for neurological diseases.

  • GlobeNewswire3 months ago

    Optinose Announces License Agreement

    Optinose (OPTN), a pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into a license agreement with Inexia whereby Inexia has obtained certain rights that will enable the use of Optinose’s Exhalation Delivery Systems (EDS) and other intellectual property in their effort to discover and develop novel therapies based on positive modulators of Orexin OX1 and OX2 for neurological diseases.

  • OptiNose, Inc. (NASDAQ:OPTN): Time For A Financial Health Check
    Simply Wall St.4 months ago

    OptiNose, Inc. (NASDAQ:OPTN): Time For A Financial Health Check

    Investors are always looking for growth in small-cap stocks like OptiNose, Inc. (NASDAQ:OPTN), with a market cap of US$248m. However, an important fact which most ignore is: how financially healthy Read More...

  • Benzinga4 months ago

    The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

    Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...

  • GlobeNewswire4 months ago

    Investor Expectations to Drive Momentum within eBay, Pulse Biosciences, Evolus, Weibo, OptiNose, and The Descartes Systems Group — Discovering Underlying Factors of Influence

    NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire4 months ago

    Optinose Announces Update to License Agreement with Avanir Pharmaceuticals for ONZETRA XSAIL  

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company received written notice from Avanir Pharmaceuticals, Inc. of its election to terminate the License Agreement to develop and commercialize ONZETRA® XSAIL® in the United States, Canada, and Mexico. Upon termination of the license agreement, Optinose may elect to continue to commercialize ONZETRA XSAIL itself or through a new licensee. “Optinose intends to evaluate its options with respect to the future of ONZETRA XSAIL,” stated CEO Peter Miller.

  • GlobeNewswire4 months ago

    Optinose Announces First Patient Enrolled in Clinical Trial of XHANCE for Chronic Sinusitis

    YARDLEY, Pa., Dec. 10, 2018 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, announced.

  • GlobeNewswire5 months ago

    Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 2018 Prescriptions for Success Healthcare Conference on December 12, 2018, at 11:00 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 30 days following the conclusion of the event.

  • Is OptiNose, Inc. (NASDAQ:OPTN) A Good Stock To Buy?
    Insider Monkey5 months ago

    Is OptiNose, Inc. (NASDAQ:OPTN) A Good Stock To Buy?

    At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]

  • OptiNose (OPTN) Reports Q3 Loss, Tops Revenue Estimates
    Zacks5 months ago

    OptiNose (OPTN) Reports Q3 Loss, Tops Revenue Estimates

    OptiNose (OPTN) delivered earnings and revenue surprises of 10.29% and 21.15%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press5 months ago

    OptiNose: 3Q Earnings Snapshot

    The Yardley, Pennsylvania-based company said it had a loss of 61 cents per share. The specialty pharmaceutical company posted revenue of $1.9 million in the period. OptiNose shares have decreased 45 percent ...

  • GlobeNewswire5 months ago

    Optinose Reports Third Quarter 2018 Financial Results and Recent Operational Highlights

    Company reports third quarter net XHANCE revenue of $1.9 million Company reports 42% monthly XHANCE prescription growth from August to October Conference call and webcast to.

  • GlobeNewswire6 months ago

    Optinose to Report Third Quarter 2018 Financial Results and Corporate Updates on November 13, 2018

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the third quarter 2018, before market open on Tuesday, November 13, 2018. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.

  • Business Wire8 months ago

    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against OptiNose, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of OptiNose, Inc. (“OptiNose” or “the Company”) (NASDAQ: OPTN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • Business Wire8 months ago

    INVESTOR ALERT: Investigation of OptiNose Announced by Holzer & Holzer

    Holzer & Holzer, LLC is investigating whether OptiNose, Inc. complied with the federal securities laws. On August 14, 2018, OptiNose issued financial results for the quarter ended June 30, 2018 and reported a net loss of $24.6 million.